肾移植前使用达雷妥尤单抗与T细胞介导的排斥反应:一例病例报告
本文报告一例低免疫风险活体供肾移植受者,因多发性骨髓瘤维持治疗在移植前接受达雷妥尤单抗,移植后早期发生严重T细胞介导的排斥反应。作者称这是首例报道的达雷妥尤单抗与体内T细胞介导排斥反应相关的病例。
要点
- 达雷妥尤单抗体外研究显示可增加CD4阳性细胞毒性T细胞和CD8阳性辅助性T细胞。
- 本例为低免疫风险活体供肾移植受者,移植前因多发性骨髓瘤维持治疗使用达雷妥尤单抗。
- 作者报告了首例达雷妥尤单抗使用与早期严重T细胞介导排斥反应相关的病例。
核心结论
- 作者报告了首例达雷妥尤单抗使用与低免疫风险活体供肾移植受者早期严重T细胞介导排斥反应相关的病例。
研究设计与样本
- 病例报告:一例低免疫风险活体供肾移植受者,移植前因多发性骨髓瘤维持治疗接受达雷妥尤单抗。
主要发现
- 该受者移植后发生早期严重T细胞介导的排斥反应。
- 体外研究显示达雷妥尤单抗可显著增加外周血和骨髓中CD4阳性细胞毒性T细胞和CD8阳性辅助性T细胞群体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is growing interest in daratumumab in the solid organ transplant realm owing to the potential immunomodulatory effects on CD38-expressing cells, primarily plasma cells, as they have a key role in antibody production. In particular there is interest in use of daratumumab for desensitization and potential treatment for antibody-mediated rejection. However, ongoing investigation with daratumumab has shown potential immunologic concerns in vitro, with a significant increase in populations of CD4-positive cytotoxic T cells and CD8-positive helper T cells in both peripheral blood and bone marrow that could lead to acute T cell-mediated rejection in the solid organ transplant patient. To date, there are no published reports of an association with daratumumab use and T cell-mediated rejection in vivo. In this case report we present what is to our knowledge the first documented case of an early severe T cell-mediated rejection in a low-immunologic-risk living-donor kidney transplant recipient who received daratumumab for multiple myeloma maintenance prior to transplant.
引用
- Scalzo RE, Sanoff SL, Rege AS, et al. Daratumumab Use Prior to Kidney Transplant and T Cell-Mediated Rejection: A Case Report. Am J Kidney Dis. 2023. PMID: 36623683. doi:10.1053/j.ajkd.2022.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。